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Abstract
Background: The cRGD peptide is a promising probe for early non-invasive detection of tumors.
This study aimed to demonstrate how RAFT-c(-RGDfK-)4, a molecule allowing a tetrameric
presentation of cRGD, improved cRGD-targeting potential using in vivo models of αVβ3-positive or
negative tumors.
Results:  We chose the human embryonic kidney cells HEK293(β3) (high levels of αVβ3) or
HEK293(β1) (αVβ3-negative but expressing αV and β1) engrafted subcutaneously (s.c.) in mice.
Non-invasive in vivo optical imaging demonstrated that as compared to its monomeric cRGD
analogue, Cy5-RAFT-c(-RGDfK-)4 injected intravenously had higher uptake, prolonged retention
and markedly enhanced contrast in HEK293(β3) than in the HEK293(β1) tumors. Blocking studies
further demonstrated the targeting specificity and competitive binding ability of the tetramer.
Conclusion: In conclusion, we demonstrated that Cy5-RAFT-c(-RGDfK-)4 was indeed binding to
the αVβ3 receptor and with an improved activity as compared to its monomeric analog, confirming
the interest of using multivalent ligands. Intravenous injection of Cy5-RAFT-c(-RGDfK-)4 in this
novel pair of HEK293(β3) and HEK293(β1) tumors, provided tumor/skin ratio above 15. Such an
important contrast plus the opportunity to use the HEK293(β1) negative control cell line are major
assets for the community of researchers working on the design and amelioration of RGD-targeted
vectors or on RGD-antagonists.
Background
The tripeptide sequence Arg-Gly-Asp (RGD) [1,2] is a well
known motif recognizing and interacting with integrin, a
family of transmembrane heterodimeric glycoproteins
composed of one α and one β subunits [3,4]. The struc-
ture of a cyclic pentapeptide containing RGD was opti-
mized in order to provide a high affinity and selectivity for
the αVβ3 integrin [5], an integrin overexpressed at the sur-
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face of activated endothelial cells during angiogenesis
[6,7] and in various types of tumor cells [8-11]. Radiola-
beled cRGD peptides in combination with nuclear imag-
ing techniques such as positron emission tomography
(PET) and single photon emission computed tomography
(SPECT) have been extensively studied for imaging of
αVβ3  expression in experimental tumors [12]. More
recently, the development of in vivo optical imaging tech-
niques and of various fluorescent-cRGD conjugates were
also described for imaging cancer in mice [12-18]. In addi-
tion, it was shown that presenting multiple copies of the
cRGD motif was usually associated with improved prop-
erties of the probes [16,19]. In this aim, our group has
developed a novel tetrameric molecule by grafting four
copies of cRGD onto a cyclic decapeptide platform called
RAFT (Regioselectively Addressable Functionalized Tem-
plate) [17,18,20]. When injected intravenously in nude
mice bearing s.c. human ovarian carcinoma IGROV1
tumors, expressing a low level of αVβ3, cyanine 5-labeled
RAFT-c(-RGDfK-)4 showed a better tumor contrast than its
monomeric analog [18].
In the present study, we took advantage of a particular
tumor model for addressing RGD-mediated targeting spe-
cificity in vivo. This model derived from the naturally αV-
positive and β3-negative HEK293 cell line was initially
transfected by a plasmid encoding the human β3 chain,
forming a strongly αVβ3-positive HEK293(β3) stable
clone. In addition, HEK293(β1), an αVβ3-negative control
overexpressing the β1 chain instead of the β3, had been
also established. As their parent cell line HEK293, we
show that the 2 β3 or β1 subclones are forming tumors
when injected subcutaneously into athymic nude mice.
Using these tumor models, our different RGD-based mol-
ecules and competition experiments, we demonstrate the
extremely good specificity and improved tumor accumu-
lation and retention of the Cy5-labeled RAFT-c(-RGDfK-)4
probe as compared to its monomeric analog. Since RGD-
based antiangiogenic therapies are currently under inves-
tigation, and that cRGD can also serve as a ligand in
human nuclear medicine, optimization of its specificity
and drug delivery properties is of major importance for
clinical applications.
Results
In vitro binding studies
HEK293(β3) and HEK293(β1) cells are stable transfectants
of human β3 and β1 subunit, respectively, from the human
embryonic kidney cell line. Western blot analysis showed
that αV was strongly expressed in both cell lines, and con-
firmed the successful transfection of β3 or β1 subunits (Fig
1A). This phenotype was also confirmed by FACS analysis
performed with the anti-human αVβ3 antibody [18]. These
2 cell lines, were then observed using confocal laser scan-
ning microscopy (CLSM) after incubation with Cy5-
labeled RAFT-c(-RGDfK-)4, cRGD, or RAFT-c(-RβADfK-)4.
As shown in Fig. 1B, none of these peptides bound to the
HEK293(β1) cells. As expected also, the RAFT-c(-RβADfK-
)4  control peptide did not bind to the αVβ3-positive
HEK293(β3) cells. In contrast, cRGD and RAFT-c(-RGDfK-
)4 were reacting with HEK293(β3) cells moderately and
very strongly, respectively.
Establishment of paired αVβ3-positive and αVβ3-negative 
tumor models
A s.c. inoculation of HEK293(β3) or HEK293(β1) cells in
nude mice lead to tumor formation. This suggested that
overexpression of β3 or β1 did not modify the known tum-
origenicity of the parental HEK293 cell line (see ATCC
number CRL-1573). Histological examination with
hematoxylin and eosin (H.E.) staining shows that either
HEK293(β3) or HEK293(β1) xenografts are composed of
nodular cell masses and stroma (Fig 2). Immunohisto-
chemical labeling of tumor sections shows positive αVβ3
staining in HEK293(β3) cells but not in HEK293(β1) and
a similar low to moderate vascularization as indicated by
the CD 31-labeling of both tumors. Thus expression of the
β3 chain was not lost during tumor growth and was not
affecting the tumor vasculature.
Whole body optical imaging
Nude mice bearing s.c. tumor xenografts of HEK293(β3)
or HEK293(β1) cell line received an i.v. injection of 10
nmol Cy5-labeled RAFT-c(-RGDfK-)4, cRGD, or RAFT-c(-
RβADfK-)4 and were imaged at different time points dur-
ing 2 days. As shown in Fig. 3a, four hours after injection
a stronger tumor uptake was observed for RAFT-c(-
RGDfK-)4 than for cRGD, while the control probe RAFT-
c(-RβADfK-)4 was not retained in the tumor. Interestingly,
the αVβ3-negative HEK293(β1) tumors did not take-up the
RAFT-c(-RGDfK-)4 peptide, demonstrating the specificity
of RAFT-c(-RGDfK-)4 for the αVβ3 integrin. The quantita-
tive analysis also showed that the tetramer and the mono-
mer reached similar maximal tumor uptake 5 to 30 min
postinjection (p.i.) (Fig. 3b). Between 30 min an 4 hr p.i.,
the tetramer's signal remained very elevated in the tumor
(65 472 ± 90 to 61 875 ± 3434 photons/pixel) while a
marked decrease (from 63 744 ± 3 031 to 28 349 ± 9 727
photons/pixel) was measured with the cRGD. At later
time points RAFT-c(-RGDfK-)4 always showed a better
tumor accumulation than the monomer. The negative
control probe RAFT-c(-RβADfK-)4 was rapidly washed-out
from the tumors. In normal skin, all 3 probes exhibited
similar kinetic curves, except at early time points (5 min
to 1 hr) where cRGD showed a somewhat stronger non-
specific diffusion (Fig. 3b). Finally, the tumor contrast (T/
S ratio) was markedly enhanced with RAFT-c(-RGDfK-)4.
Four hr p.i. the T/S ratio reached the value of 15.9 ± 3.6
with RAFT-c(-RGDfK-)4. This was significantly higher than
that of the monomeric cRGD (5.9 ± 2.0), or the 1.4 ± 0.1Molecular Cancer 2007, 6:41 http://www.molecular-cancer.com/content/6/1/41
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ratio obtained for the control probe. Importantly, RAFT-
c(-RGDfK-)4  did not accumulate in the αVβ3-negative
HEK293(β1) xenografts. Indeed, the measured signal
obtained with RAFT-c(-RGDfK-)4 in HEK293(β1) tumors
was similar to that of RAFT-c(-RβADfK-)4 in HEK293(β3)
tumors.
Confocal microscopic observation of RGD-Cy5 conjugate 
distribution
Tumors of mice treated as mentioned above were excised
3 or 24 hr p.i, and analyzed by CLSM imaging (Fig. 4).
Cy5-RAFT-c(-RGDfK-)4  was massively internalized by
tumor cells as shown at a higher magnification in the
insert (Fig. 4B). While virtually each tumor cell was
strongly labeled at 3 hr, it was still easily detectable in a
large proportion of tumor cells after 24 hr (data not
shown). A similar pattern was obtained with the mono-
meric cRGD although the intensity of the signal was lower
(Fig. 4C). No specific fluorescence was found with the
control peptide Cy5-RAFT-c(-RβADfK-)4 (Fig 4D).
Blocking study
In order to further establish the in vivo specificity of Cy5-
RGD conjugates, 10 nmol Cy5-RAFT-c(-RGDfK-)4 or Cy5-
cRGD were coinjected with 300 nmol unlabeled tetra-
meric RGD or 1200 nmol unlabeled monomeric cRGD.
The differences in the injected doses of unlabeled mole-
cules were calculated in order to maintain equal concen-
trations of the competing RGD motifs. As shown in Fig.
5A, the tumor uptake of Cy5-RAFT-c(-RGDfK-)4 was sig-
nificantly reduced in the presence of ''cold'' (unlabeled)
monomer and this effect was more obvious when the
''cold'' tetramer was used. As an example, at 3 hr p.i. the
signal intensities were significantly decreasing (p  <
0.0001) from 65 472 ± 80 without competitor to 34 339
± 6 402 in the presence of ''cold'' cRGD (reduction of
50%) and down to 12 894 ± 2 504 when the ''cold''
tetramer was in excess (reduction of 80%). This blocking
effect was obvious on the corresponding images (Fig. 5A,
left panel). In addition, it is important to note that the
strong decrease of the signal in the tumors was observed
(A) Western blot analysis of expressions of integrin subunits αV, β1 and β3 in HEK293(β1) and HEK293(β3) cell lines Figure 1
(A) Western blot analysis of expressions of integrin subunits αV, β1 and β3 in HEK293(β1) and HEK293(β3) cell lines. (B) Con-
focal laser scanning microscopic images of HEK293(β1) and HEK293(β3) cells incubated for 30 min at 37°C in the presence of 
0.1 μM Cy5-labeled RAFT-c(-RGDfK-)4, cRGD, or RAFT-c(-RβADfK)4. Nuclei were stained with Hoechst 33342 (blue), and 
fluorescence signal from Cy5 was pseudocolored red. Original objective: Plan-Neofluar 40x/1.30 Oil ph3.
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while the kidneys were showing identical intensities. This
indicated that, as expected, the non-specific renal uptake
of the tetrameric RGD was not affected by the presence of
the different competitors. Similarly, a reduction of at least
50 to 60 % was obtained when Cy5-cRGD was used for
labeling (Fig. 5B). The blocking effect of both competitors
was very strong even if RAFT-c(-RGDfK-)4 was slightly
more efficient.
Discussion
RGD-based peptides are certainly the most frequently
used molecules for tumor targeting and are currently in
use for selective drug delivery and tumor imaging in pre-
clinical models or in clinical trials. In this study we
present evidences that presenting four copies of the cRGD
motif on our RAFT carrier greatly improves cRGD-medi-
ated tumor targeting in vivo of αVβ3-positive tumors.
In vitro and in vivo, the αVβ3-positive HEK293(β3) cells and
tumors were very strongly recognized by Cy5-RAFT-c(-
RGDfK-)4  but not by the negative control RAFT-c(-
RβADfK-)4. In addition, the αVβ3-negative HEK293(β1)
samples remained negative after staining with the RGD or
RβAD-based peptides. Furthermore, fluorescence images
of both cultured cells and excised tumors clearly demon-
strate the stronger labeling of HEK293(β3) cells by Cy5-
RAFT-c(-RGDfK-)4 as compared to its monomeric ana-
logue, confirming the enhanced receptor binding
achieved when multiple RGD motifs are presented by a
single template. The tetrameric RGD exhibited also
stronger signal intensity in tumors, longer retention and
much better contrast as compared to its monomeric ana-
logue. Such effects could be explained by its augmented
receptor-binding affinity due to the polyvalency effect
[17,19,20] and increased molecular size which certainly
delays the circulation and tumor retention time of the
Cy5-RAFT-c(-RGDfK-)4. Finally, the active internalization
of the Cy5-RAFT-c(-RGDfK-)4 probe may also contribute
to its improved accumulation in the tumor cells. As
shown on the tumor sections, the internalization was very
strong since most of the signal was coming from the cyto-
plasm of the target cells. This suggests that such vector
could be highly efficient to deliver drugs intracellularly.
Multivalent presentation of ligands is improving signifi-
cantly the targeting of tumors and several highly efficient
targeting molecules allowing a multivalent presentation
of RGD have been described [21-27]. Nonetheless, for
some of these molecules the chemical formulation is
poorly characterized and thus the number of ligand
motifs being added on a polymer is random and cannot
be controlled. In addition, the conformation of these mol-
ecules is not constrained. It is thus impossible to separate
spatially the different biological functions presented by a
single molecule nor it is possible to know its exact struc-
ture. These problems are avoided using RAFT-c(-RGDfK-
)4 because the chemistry we use is regio- and chemo-selec-
tive. Thus the synthesis and purification of the final mol-
ecules are perfectly controlled even at gram scale. In
addition, the RAFT architecture allows a spatial separation
between the targeting and "drug-delivery" domains.
Finally, RAFT is also interesting because its geometry
allows a presentation of four RGD motifs at a very high
density on its small surface.
To further confirm the receptor binding specificity of the
Cy5-labeled RGD tetramer, blocking experiments were
performed in vivo. In agreement with other reports using
the monomeric cRGD [13,14,16], we observed an almost
complete inhibition of cRGD accumulation in the pres-
ence of an excess of "cold" cRGD or RAFT-c(-RGDfK-)4.
More interestingly the opposite experiment showed that
while cRGD was able to block roughly 50% of Cy5-RAFT-
c(-RGDfK-)4 accumulation, the presence of an excess of
unlabeled tetramer was reducing by more than 80% the
Cy5-RAFT-c(-RGDfK-)4 signal in the tumor. Finally Cy5-
RAFT-c(-RGDfK-)4 shows higher renal uptake than Cy5-
cRGD. This was observed in either tumor-bearing or nor-
mal mice. This renal retention is likely to be non-specific
since it was not modified by the presence of an excess of
unlabeled tetramer or monomer.
Hematoxylin-eosin (H.E.) staining and immunohistochemical  staining with anti-CD31 and anti-αVβ3 in HEK293(β1) or  HEK293(β3) s.c. xenografts. Original magnification: × 20  objective lenses Figure 2
Hematoxylin-eosin (H.E.) staining and immunohistochemical 
staining with anti-CD31 and anti-αVβ3 in HEK293(β1) or 
HEK293(β3) s.c. xenografts. Original magnification: × 20 
objective lenses.
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HEK293(β3) and HEK293(β1) might be an interesting
duo of tumors forming from cell lines which differ only
by their integrin β3 status. One is αVβ3-positive and the
other is αVβ3-negative. Another model, M21 was also
described. The αVβ3-positive M21 and its αVβ3-negative
variant M21-L human melanoma cell lines were the first
reported paired models for in vivo evaluation of αVβ3
receptor binding specificity of RGD peptides [13,28,29].
M21-L cells were selected and maintained as a stable vari-
ant of M21 unable to synthesize the α chain but with nor-
mal levels of the β chain [30]. Here, we present another
duo of αVβ3 positive and negative s.c. tumor xenografts.
HEK293(β3) and HEK293(β1) cell lines are stable trans-
fectants of the human embryonic kidney cell line
HEK293, overexpressing the human integrin β3 and  β1
subunits respectively. While the original HEK293 cells
express high levels of αV but negligible levels of α5, β3 and
β1, HEK293(β3) expresses impressive amounts of αVβ3,
and HEK293(β1) cells mainly form the αVβ1  receptor
(another known receptor of fibronectin and vitronectin).
This model is of great interest for the in vivo study of RGD-
based targeting vectors since tumor/skin ratio of more
than 15 can be obtained. Such a large dynamic is allowing
precise measurements of the impact of treatments or
chemical modifications possibly affecting the RGD-medi-
ated targeting. In addition, the negative control cell line is
a major asset to confirm the specificity of these RGD-
delivery systems.
(a) Representative fluorescence images of Swiss nude mice bearing HEK293(β1) or HEK293(β3) s.c. tumors after i.v. injection  of 10 nmol Cy5-labeled RAFT-c(-RGDfK-)4, cRGD, or RAFT-c(-RβADfK)4 Figure 3
(a) Representative fluorescence images of Swiss nude mice bearing HEK293(β1) or HEK293(β3) s.c. tumors after i.v. injection 
of 10 nmol Cy5-labeled RAFT-c(-RGDfK-)4, cRGD, or RAFT-c(-RβADfK)4. All images were displayed at the indicated LUT 
(look-up-table) value. The values shown in each image represent the range of minimal to maximum signal intensity. T and K 
indicate tumor and kidney, respectively. (b) Time-courses of fluorescence intensities in tumors and skin as well as ratios of 
tumor vs. skin after i.v. injection of 10 nmol Cy5-labeled RAFT-c(-RGDfK-)4, cRGD, or RAFT-c(-RβADfK-)4. Solid circles: 
HEK293(β3) + Cy5-RAFT-c(-RGDfK-)4; Solid squares: HEK293(β3) + Cy5-cRGD; Solid triangles: HEK293(β3) + Cy5-RAFT-c(-
RβADfK-)4; Open circles: HEK293(β1) + Cy5-RAFT-c(-RGDfK-)4. The fluorescence intensity was recorded as photons per 
pixel for a specified ROI. Data are expressed as means ± SD (n = 3–4).
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Conclusion
Using such paired tumor models, we demonstrated that
RAFT-c(-RGDfK-)4 is specific for the αVβ3 receptor and
internalized. In addition, due to its multifunctional back-
bone, it can carry multiple biological functions on a sin-
gle, spatially and chemically defined molecule. Finally,
the production of large quantities of perfectly controllable
batches makes of RAFT-c(-RGDfK-)4 a powerful and versa-
tile synthetic vector for clinical applications like targeted-
drug delivery or molecular imaging of cancer. Ultimately,
our goal will be to combine these two applications and to
use RAFT-c(-RGDfK-)4 for imaging and quantification of
its targeted-drug delivery efficiency.
Methods
RGD-Peptides Synthesis and Fluorescent Labeling
The detailed protocol for synthesis of RGD peptides was
reported previously [20]. Here, a brief description was
given below for the strategy of RGD multimerization and
fluorescence labeling. RAFT is a cyclic decapeptide (c [-
Lys(Boc)-Lys(Alloc)-Lys(Boc)-Pro-Gly-Lys(Boc)-
Lys(Alloc)-Lys(Boc)-Pro-Gly-]) with up to six lysine resi-
dues. Protection of the lysine in position 1, 3, 6, or 8 and
of the two in positions 2 and 7 results in RAFT molecules
having two orthogonally addressable domains pointing
on either side of the cyclopeptide backbone. On the upper
face, four copies of the c [-RGDfK-] peptide were grafted
Confocal laser scanning microscopic images of HEK293(β3) s.c. tumors dissected at 3 hr after i.v. injection of 10 nmol Cy5- labeled RAFT-c(-RGDfK-)4 (A, B), cRGD (C), or RAFT-c(-RβADfK-)4 (D) Figure 4
Confocal laser scanning microscopic images of HEK293(β3) s.c. tumors dissected at 3 hr after i.v. injection of 10 nmol Cy5-
labeled RAFT-c(-RGDfK-)4 (A, B), cRGD (C), or RAFT-c(-RβADfK-)4 (D). Paraformaldehyde-fixed cryosections were incu-
bated with Hoechst 33342 for nuclear staining (blue). Signal from Cy5 was pseudocolored red. Original objective: Plan-
Apochromat 63x/1.4 Oil; an additional zoom of 4x was added for the insert in B.
RAFT-c(-RGDfK-)4
cRGD RAFT-c(-RßADfK-)4
3 hr post-injection 3 hr post-injection zoom 4x
3 hr post-injection 3 hr post-injection
AB
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via an oxime bond (R1-O-N = C-R2) for recognition of the
integrin. On the opposite side of RAFT, Cy5 mono NHS
(N-hydroxysuccinimide) ester (Amersham Biosciences,
Uppsala, Sweden) was added on the lysine chain (c [-
KKKPGKAKPG-]) [17]. As a negative control probe, Cy5-
labeled RAFT-c(-RβADfK-)4 was also synthesized in a sim-
ilar way. Changing the G amino-acid by a β-Ala abolishes
RGD-mediated affinity for the integrins. All the probes
were dissolved in phosphate-buffered saline (PBS) for the
in vitro and in vivo application.
Cell Lines and Culture Conditions
HEK293(β3) and HEK293(β1) cells, stable transfectants of
human β3 and β1 subunit, respectively, from the human
embryonic kidney cell line (kindly provided by J-F. Gour-
vest, Aventis, France) were cultured in DMEM enriched
with 4.5 g.L-1  glucose and supplemented with 1%
glutamine, 10% fetal bovine serum (FBS), 50 units/ml
penicillin, 50 μg/ml streptomycin and 700 μg/ml
Geneticin (G418 sulfate, Gibco, Paisley, UK). The 2 cell
lines were cultured at 37°C in a humidified 95% air:5%
CO2 atmosphere.
Western blot analysis of integrin subunit expression
Cells were lysed in RIPA lysis buffer (50 mM Tris-HCl, pH
7.5, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1%
SDS, 1% Nonidet P-40, 1 mM NaF, 1 mM Na3VO4, 0.5
mM phenylmethylsulfonyl fluoride, 10 μg/ml for each of
leupeptin, aprotinin, and pepstatin) for 30 min on ice,
and then the lysates were centrifuged at 17000 × g for 15
minutes at 4°C. The protein concentration of the superna-
tant was quantified using a protein assay kit (Bio Rad
Labs., Richmond, CA). Aliquots of protein (40 μg) were
subjected to electrophoresis on 7–10% polyacrylamide
Blocking of Cy5-labeled RGD peptide accumulation in HEK293(β3) s.c. tumors by coinjection with unlabeled RGD peptide Figure 5
Blocking of Cy5-labeled RGD peptide accumulation in HEK293(β3) s.c. tumors by coinjection with unlabeled RGD peptide. (A) 
Tumor-bearing mice received i.v. injection of 10 nmol Cy5-RAFT-c(-RGDfK-)4 alone (a), or coinjected with 1200 nmol cRGD 
(b) or 300 nmol RAFT-c(-RGDfK-)4 (c). (B) Tumor-bearing mice received i.v. injection of 10 nmol Cy5-cRGD alone (a), or 
coinjected with 1200 nmol cRGD (b) or 300 nmol RAFT-c(-RGDfK-)4 (c). Left panel: representative fluorescence images at 2 
hr p.i.; Right panel: kinetics of fluorescence intensities in tumors. T, K and Int indicate tumor, kidney and intestine, respectively. 
Data are expressed as means ± SD (n = 2–4).
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gels containing 0.1% SDS, followed by electrophoretic
transfer onto PVDF-membranes, Hybond™-P (Amersham
Biosciences UK Limited, Little Chalfont, Buckingham-
shire, UK). The membranes were then incubated with pri-
mary antibody: rabbit anti-human integrin αV polyclonal
antibody (1:5000; Chemicon International, Inc., Temec-
ula, CA), rabbit anti-integrin β1 tail serum (1:1500; kindly
provided by Dr C. Albiges-Rizo, Grenoble, France) or
mouse anti-human β3 monoclonal antibody (clone VI-
PL2, 1:100; BD Biosciences PharMingen, San Diego, CA).
To monitor equal protein loading, membranes were also
probed for actin using rabbit anti-actin polyclonal anti-
body (1:1000; Sigma) or for HSP70 using mouse anti-
HSP70 monoclonal antibody (1:5000; Affinity BioRea-
gents Inc.). For visualization, horseradish peroxidase
(HRP)-conjugated secondary antibodies, followed by
ECL™ immunodetection (Amersham Biosciences UK Lim-
ited) were used.
Animal, Tumor Models and Histochemistry
Animal procedures were in agreement with the EEC guide-
lines. Female athymic Swiss nude mice, purchased from
Janvier (Le Genest Saint Isle, France) at 6–8 weeks of age
were used and maintained under specific pathogen-free
conditions. Subcutaneous (s.c.) injection of 20 × 106
HEK293(β3) or HEK293(β1) cells suspended in 200 μl of
PBS into the right flank of mice resulted in formation of
6–8 mm-diameter tumors after 4–6 weeks. Immunostain-
ing with mouse anti-human integrin αVβ3 monoclonal
antibody, clone LM609 (1:100; Chemicon) was per-
formed on acetone-fixed cryosections using M.O.M.
immunodetection (peroxidase) Kit (Vector laboratories,
Inc., Burlingame, CA). Rat anti-mouse CD31 monoclonal
antibody, clone MEC13.3 (1:3000; BD Biosciences
PharMingen) staining was performed on methanol-fixed
cryosections using Strept-. ABComplex/HRP immunode-
tection Kit (DakoCytomation). The nuclei were counter-
stained with hematoxylin.
In Vitro Studies
Cells were seeded on sterilized 18-mm-diameter glass cov-
erslips in 12-well plates (3 × 105 cells per well), and incu-
bated overnight at 37°C. Afterwards, the cells were
washed with PBS and incubated at 37°C in the presence
of Cy5-labeled peptides RAFT-c(-RGDfK-)4, cRGD or
RAFT-c(-RβADfK-)4 at final concentration of 0.1 μM for 30
min. They were then washed with PBS, fixed with 2%
paraformaldehyde at room temperature for 10 min. The
nuclei were stained with 5 μM Hoechst 33342, and the
coverslips were inverted onto glass slides using Mowiol
(Calbiochem, San Diego, CA) mounting medium. The
slides were observed with a confocal laser scanning micro-
scopy (CLSM) (LSM510, Zeiss, France).
In Vivo Optical Imaging of Tumor-bearing Mice
The mice bearing s.c. HEK293(β3) or HEK293(β1) tumors
at diameter of 6–8 mm were used for imaging experi-
ments. They received intravenous (i.v.) injection of Cy5-
labeled peptides RAFT-c(-RGDfK-)4, cRGD or RAFT-c(-
RβADfK-)4 at 10 nmol for each mouse (n = 3–4 for each
probe). For the blocking experiments, s.c. HEK293(β3)
tumor-bearing mice (n = 2–4 for each group) received
coinjection of Cy5 labeled RAFT-c(-RGDfK-)4 or cRGD
(10 nmol/mouse) together with unlabeled RAFT-c(-
RGDfK-)4  (300 nmol/mouse) or cRGD (1200 nmol/
mouse). Four times higher molar concentration of cRGD
was used than that of tetramer to have same number of
cRGD motifs.
Fluorescence reflectance imaging was performed using a
Hamamatsu optical imaging system described previously
[17,18]. In brief, imaging was carried out in a dark box,
and anesthetized animal was illuminated with a mono-
chromatic 633 nm light (50 μW.cm-2). The re-emitted flu-
orescence was filtered using a colored glass filter RG 665
(optical density > 5 at the excitation wavelength 633 nm)
and collected with a cooled (-70°C) digital charge-cou-
pled device (CCD) camera (Hamamatsu digital camera
C4742-98-26LWGS, Hamamatsu Photonics K.K., Japan).
All fluorescence images were acquired using 100 ms of
exposure time, with other related parameters kept con-
stant throughout the experiment. Images were acquired as
16-bit TIFF files which can provide a dynamic of up to
65535 grey levels. Image processing used in this study,
including setting LUT (look-up-table) range and measure-
ment of the fluorescence intensity for each region of inter-
est (ROI), were performed using the Wasabi software
(Hamamatsu). It is also important to note that all the
images are presented without background subtraction.
For quantifying tumor contrast, the mean fluorescence
intensities of the tumor area (T) and that of the distant
skin area (S) were calculated; dividing T by S produced the
ratio between tumor tissues and background level.
Histological Distribution of RGD-peptides in Tumors
At 3 and/or 24 hr after i.v. injection of 10 nmol of Cy5-
labeled RAFT-c(-RGDfK-)4, cRGD or RAFT-c(-RβADfK-)4,
the mice were euthanized and tumors were excised, frozen
in liquid nitrogen and stored at -80°C. Sections of 20–30
μm thickness were fixed with 2% paraformaldehyde at
room temperature for 10 min. The nuclei were stained
with 5 μM Hoechst 33342, and the coverslips were
mounted using Mowiol and kept at 4°C in the dark until
observation using CLSM.
Statistical Analysis
All the data are given as mean ± standard (SD) of n inde-
pendent measurements. Statistical analysis was performedMolecular Cancer 2007, 6:41 http://www.molecular-cancer.com/content/6/1/41
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using two-tailed nonparametric Mann-Whitney t-test. Sta-
tistical significance was assigned for values of p < 0.05.
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